| NCT ID | NCT06393920 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medtronic Cardiac Ablation Solutions |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,950 participants |
| Start Date | 2024-07-23 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,950 participants in total. It began in 2024-07-23 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The PulseSelect™ PFA Global Registry is a prospective, global, multi-center, observational post-approval study. Subjects will be treated with the PulseSelect™ PFA System and followed according to SOC.
Eligibility Criteria
Inclusion Criteria: * Subject is ≥ 18 years of age or minimum age as required by local regulations. * Subject has been diagnosed with atrial fibrillation (AF) * Planned procedure using commercially available PulseSelect™ PFA System. * Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements. Exclusion Criteria: * Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager. * Subject with exclusion criteria required by local law.
Contact & Investigator
Khaldoun Tarakji, MD
STUDY DIRECTOR
Medtronic CAS Chief Medical Officer
Frequently Asked Questions
Who can join the NCT06393920 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06393920 currently recruiting?
Yes, NCT06393920 is actively recruiting participants. Contact the research team at josman.suri@medtronic.com for enrollment information.
Where is the NCT06393920 trial being conducted?
This trial is being conducted at Richmond, Australia, Hasselt, Belgium, Vancouver, Canada, Montreal, Canada and 11 additional locations.
Who is sponsoring the NCT06393920 clinical trial?
NCT06393920 is sponsored by Medtronic Cardiac Ablation Solutions. The principal investigator is Khaldoun Tarakji, MD at Medtronic CAS Chief Medical Officer. The trial plans to enroll 1,950 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.